{"id":136355,"date":"2025-10-21T16:01:08","date_gmt":"2025-10-21T16:01:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/136355\/"},"modified":"2025-10-21T16:01:08","modified_gmt":"2025-10-21T16:01:08","slug":"this-healthcare-stock-is-up-1000-outpacing-nvidia-tesla-and-apple-combined","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/136355\/","title":{"rendered":"This Healthcare Stock Is Up 1,000%, Outpacing Nvidia, Tesla, and Apple Combined"},"content":{"rendered":"<p>Technology stocks get a lot of hype these days. That&#8217;s particularly true for those involved in <a href=\"https:\/\/www.fool.com\/terms\/g\/generative-ai\/\" rel=\"nofollow noopener\" target=\"_blank\">generative artificial intelligence<\/a>. However, there have been outstanding performers in other sectors this year.<\/p>\n<p>For instance, <strong>Oncology Institute <\/strong>(<a class=\"ticker-symbol\" href=\"https:\/\/www.fool.com\/quote\/nasdaq\/toi\/\" rel=\"nofollow noopener\" target=\"_blank\">TOI<\/a> -0.83%), a provider of oncology care, has seen its stock price soar 1,130% through Oct. 16. That&#8217;s outpaced popular stocks, such as <strong>Nvidia <\/strong>and <strong>Tesla<\/strong>, which gained 35.4% and 6.2%, respectively, while <strong>Apple<\/strong>&#8216;s lost 1.2%. <\/p>\n<p>It&#8217;s time to take a step back to explore Oncology Institute&#8217;s business.<\/p>\n<p><img decoding=\"async\" alt=\"A physician explaining something to a patient.\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/10\/1761062468_277_\" \/><\/p>\n<p class=\"caption\">Image source: Getty Images.<\/p>\n<p>Understanding the company<\/p>\n<p>Oncology Institute, started in 2007, provides a range of cancer care. This includes physician care, infusions, and radiation. It also provides pharmacy services and clinical trials.<\/p>\n<p>It aims to provide these services under value-based contracts through which Oncology Institute receives a fee. This arrangement offers savings to insurance companies and patients while putting the onus on Oncology Institute to provide high-quality healthcare in a cost-efficient manner. <\/p>\n<p>The company operates in 16 markets across five states, so it remains small. Nonetheless, it has been growing revenue rapidly. Oncology Institute&#8217;s second-quarter top line increased 21.5% to $119.8 million. <\/p>\n<p>However, the company continues to lose money. It reported an operating loss under <a href=\"https:\/\/www.fool.com\/terms\/g\/generally-accepted-accounting-principles\/\" rel=\"nofollow noopener\" target=\"_blank\">g<\/a>enerally accepted accounting principles (<a href=\"https:\/\/www.fool.com\/terms\/g\/generally-accepted-accounting-principles\/\" rel=\"nofollow noopener\" target=\"_blank\">GAAP<\/a>) of $11.2 million, although that&#8217;s narrower than last year&#8217;s $16.4 million loss.<\/p>\n<p>Future prospects<\/p>\n<p>Companies that make the U.S. healthcare system more cost-effective and produce better outcomes should be rewarded with high revenue and profit growth. Still, it&#8217;s unclear when or if Oncology Institute will achieve profitability. With the stock soaring this year, it may have gotten ahead of itself.<\/p>\n<p><a href=\"https:\/\/www.fool.com\/author\/20204\/\" rel=\"nofollow noopener\" target=\"_blank\">Lawrence Rothman<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Nvidia, and Tesla. The Motley Fool has a <a href=\"https:\/\/www.fool.com\/legal\/fool-disclosure-policy\/\" rel=\"nofollow noopener\" target=\"_blank\">disclosure policy<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Technology stocks get a lot of hype these days. That&#8217;s particularly true for those involved in generative artificial&hellip;\n","protected":false},"author":2,"featured_media":136356,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[18,135,475,474,19,17],"class_list":{"0":"post-136355","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-eire","9":"tag-health","10":"tag-health-care","11":"tag-healthcare","12":"tag-ie","13":"tag-ireland"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/136355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=136355"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/136355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/136356"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=136355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=136355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=136355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}